HFE-haemochromatosis is a genetic disorder resulting from mutations of the HFE gene. It primarily affects people of Northern European descent. Clinical manifestations result from the progressive deposition of iron into various organs including the liver. An elevated serum ferritin concentration greater than 300 microgram/L and a transferrin saturation of greater than 45% will identify almost all patients with HFE-haemochromatosis. HFE genotyping confirms the diagnosis. In some patients, liver biopsy may still be necessary as the degree of hepatic fibrosis has prognostic implications.
Introduction
HFe-haemochromatosis is the most frequent inherited cause of iron overload in humans. The condition is due to an inborn 
Genetics
The HFe gene is located on chromosome six. It codes for a cell surface protein which is involved in the regulation of iron An Australian study of people of Northern european descent reported symptoms and signs of iron overload in 28.4% of males and 1.2% of females who were C282Y homozygous. 2 The same study found that symptomatic iron overload was rare among compound heterozygotes (0.2%).
Transferrin saturation
The first approach to diagnosing HFe-haemochromatosis is the assessment of indirect markers of iron stores. Fasting transferrin saturation is considered to be the most sensitive screening test for HFe-haemochromatosis.
An elevated fasting transferrin saturation greater than 50% in women and 60% in men of Northern european descent has a positive predictive value of 86% for the diagnosis of HFe-haemochromatosis. 3 Lowering the threshold transferrin saturation to 45% improves the sensitivity and negative predictive value, but reduces the positive predictive value.
In an Australian population study, a value of 45% was able to correctly identify 98% of C282Y homozygotes. 4 However, using this value will also detect heterozygotes who do not need further investigations. Approximately 30% of C282Y heterozygotes have a transferrin saturation greater than 45%.
The combination of an elevated fasting transferrin saturation (greater than 45%) and an elevated serum ferritin has a negative predictive value of 97%. This exceeds the accuracy of either test used alone. 3 
Serum ferritin concentration
Raised serum concentrations of ferritin occur in a number of different conditions including iron overload. There are also several causes of iron overload (see box). In the setting of iron overload, the serum ferritin tends to reflect total body iron stores and generally increases with progressive iron loading. 5 Abnormal laboratory results www.australianprescriber.com An Australian population-based study reported a sensitivity of 50% and specificity of 87% for serum ferritin concentrations greater than 300 microgram/L for the diagnosis of C282Y homozygosity. 6 Higher serum ferritin thresholds have been studied in an attempt to lower the rate of false positives and increase the positive predictive value for the detection of HFe-haemochromatosis. For example, a population-based study screening 29 699 people identified 59 patients with a serum ferritin concentration greater than 1000 microgram/L, of whom 24 had HFe-haemochromatosis with 20 people being C282Y homozygous. 7 Serum ferritin concentrations greater than 1000 microgram/L are associated with a higher risk of cirrhosis and may be used as an indication for liver biopsy. 8 A French study reported a sensitivity of 98%, a specificity of 72% and a positive predictive value of 55% when using a serum ferritin concentration of 1000 microgram/L to predict the presence of severe fibrosis among C282Y homozygotes. 9 
HFE genotyping
The diagnostic evaluation of people with suspected HFe-haemochromatosis changed following the discovery of the HFe gene in 1996. 1 Blood tests for HFe genotyping should be considered in people with suspected iron overload, patients with a family history of HFe-haemochromatosis and cases of unexplained chronic liver disease with an increased transferrin saturation 12 (see Fig. 1 ). Genetic screening for HFe-haemochromatosis in the general population is not recommended because the disease penetrance is low. 12 Most patients with HFe-haemochromatosis are C282Y homozygotes and the majority of the remaining cases are compound heterozygotes (C282Y/H63D). H63D homozygosity does not result in significant hepatic iron overload and an elevated serum ferritin in these patients is usually the result of hepatic steatosis or excess alcohol consumption. 13 
other tests
Following the advent of HFe genotyping, liver biopsy is no longer necessary to make a diagnosis of HFehaemochromatosis. However, liver biopsy is still required to stage hepatic fibrosis, especially as patients with serum ferritin concentrations greater than 1000 microgram/L are more likely to have cirrhosis. 9 Diagnosing the presence of cirrhosis as an alternative to liver biopsy. 15 
Family screening
Siblings of patients with HFe-haemochromatosis should undergo HFe genotyping as they have a 25% chance of being affected. 12 In clinical practice, most family members also have serum iron indices measured to assess their body iron stores.
Whether individuals are screened depends upon several factors including their age and health status, and the attitudes of the family. 12 In the case of children who have a parent with HFe-haemochromatosis, HFe genotyping of the unaffected 
HFE-haemochromatosis confirmed
Refer for consideration of liver biopsy to determine extent of fibrosis Venesection, family screening and hepatocellular carcinoma surveillance www.australianprescriber.com parent may be of value. 16 In such cases, the likelihood of genetic susceptibility and the need for testing of children later in life can be established.
Conclusion
HFe-haemochromatosis is a common genetic disorder primarily affecting people of North european descent. early diagnosis and treatment prevent progressive disease. It is important that people with characteristics associated with severe hepatic fibrosis or cirrhosis are identified and managed appropriately.
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